Regular Article | Open | Published:

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer

British Journal of Cancer volume 80, pages 495503 (1999) | Download Citation

Subjects

Abstract

A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity, stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2 ± 13.1 μg l–1) correlated with TIMP-1 measured in EDTA plasma (mean 73.5 ± 14.2 μg l–1) from the same individuals in a set of 100 healthy blood donors (Spearman’s rho = 0.62, P < 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes’ stage D colorectal cancer was 240 ± 145 μg l–1 and a Mann–Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292 ± 331 μg l–1). The results show that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer. It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients.

Change history

  • Corrected online 16 November 2011

References

  1. , , , , & (1994). Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 70: 506–512.

  2. , , , , , & (1993). Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197–250.

  3. , , & (1991). Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 11: 76–85.

  4. , , , , , & (1990). Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 10: 285–291.

  5. , , & (1985). Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci USA 82: 2779–2783.

  6. , , , , , , , , , & (1996). 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 15: 102–109.

  7. , , , , & (1992). Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701–708.

  8. , , , & (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563–1571.

  9. (1996). TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2: 1369–1372.

  10. , , , , & (1998). Plasminogen activator inhibitor type 1 (PAI-1) in cancer: a potential new target for antiinvasive and antimetastatic therapy. Drugs of the Future 23: 873–883.

  11. , , , , & (1993). A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta 220: 31–45.

  12. , , , , & (1996). Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem 42: 2043–2045.

  13. , , , , & (1996). Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 56: 3196–3198.

  14. , , , & (1992). Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583–4591.

  15. , , , & (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29–32.

  16. , & (1985). Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci 73: 105–119.

  17. , , , , & (1996). What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? Clin Chim Acta 254: 97–100.

  18. , , , , , , , , , , & (1997). Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 28: 613–622.

  19. & (1993). The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol 18: 123–127.

  20. , , , & (1992a). Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 84: 1017–1022.

  21. , , & (1992b). Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 10: 365–370.

  22. , , & (1993). Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry 32: 1583–1592.

  23. , , , & (1989). A sandwich enzyme immunoassay for collagenase inhibitor using monoclonal antibodies. Matrix 9: 1–6.

  24. , & (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336.

  25. & (1995). Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14: 351–362.

  26. (1992). The matrix-degrading metalloproteinases. Bioessays 14: 455–463.

  27. , , , , , , , & (1997). Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76: 531–536.

  28. , , & (1990). Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res 50: 6162–6170.

  29. , , , & (1992). Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res 28: 213–230.

  30. , , , , & (1991). The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30: 8097–8102.

  31. , , , & (1995). Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55: 267–275.

  32. , & (1989). Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374–17378.

  33. , & (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7: 1434–1441.

  34. , & (1996). Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7: 147–154.

  35. , , & (1993). Tumor invasion, proteolysis, and angiogenesis. J Neurooncol 18: 89–103.

  36. , , , & (1985). Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll Relat Res 5: 167–179.

  37. , , , , & (1989). SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264: 17213–17221.

  38. , & (1996). Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer 69: 131–134.

  39. , , , , , , & (1995). Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 76: 700–708.

Download references

Author information

Affiliations

  1. The Finsen Laboratory, Copenhagen University Hospital, Strandboulevarden 49, 2100 Copenhagen, Denmark

    • M N Holten-Andersen
    • , A N Pedersen
    • , I J Christensen
    • , G Høyer-Hansen
    • , N Brünner
    •  & R W Stephens
  2. Strangeways Laboratories, Cambridge University, Cambridge, UK

    • G Murphy
  3. Department of Oncology, Herlev Hospital, Herlev Ringvej, 2730 Herlev, Denmark

    • A N Pedersen
  4. Department of Gastroenterology, Hvidovre Hospital, Kettegårds Alle, 2650 Hvidovre, Denmark

    • H J Nielsen

Authors

  1. Search for M N Holten-Andersen in:

  2. Search for G Murphy in:

  3. Search for H J Nielsen in:

  4. Search for A N Pedersen in:

  5. Search for I J Christensen in:

  6. Search for G Høyer-Hansen in:

  7. Search for N Brünner in:

  8. Search for R W Stephens in:

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/sj.bjc.6690384